Dallán Ryan

This report on alternative data for energy investing examines the use of alternative data in the energy sector, providing insights beyond traditional market data. By incorporating unique data types like satellite imagery and economic trade information, investors can avoid common biases and gain a more accurate historical view of the market.

This white paper explores the significance and application of Point-in-Time (PIT) data, which captures information at a specific moment, providing a snapshot of data distinct from time-series data. PIT data, critical for eliminating biases such as look-ahead and look-behind biases, is crucial for systematic firms to avoid “survivorship bias” by reflecting the true historical landscape without alterations caused by company changes or corrections.

This white paper delves into the profound shifts within the tech sector brought on by the COVID-19 pandemic, spotlighting the accelerated adoption of remote work practices and the heightened demand for various technological products and services. In detailing the tech industry’s journey towards recovery in 2023, the paper underscores the sector’s resilience and its capacity to adapt, fueled by a resurgent interest in AI alongside progress in other technological domains. Data-driven insights emerge as crucial tools for comprehending the fluid market landscape.

This white paper explores the impact of alternative data sources on the healthcare industry, emphasizing their role in enhancing investment decisions in healthcare startups, therapies, and market trends. It delves into patient-generated data, wearables, mobile health apps, social media discussions, and electronic health records (EHRs) as key non-traditional data sources. The report segments healthcare data into four primary categories: R&D and clinical trials, claims data, medical devices data, and other relevant datasets, underscoring the transformative role of AI in healthcare processes. The paper includes sections on investment trends in pharma and biomed, data availability and its applications, the evolution of the pharma industry through AI, real-world case studies demonstrating successful data utilization, and compliance considerations for investors. This summary offers a glimpse into the comprehensive insights provided in the full report by Eagle Alpha, which further includes additional case studies and details on alternative data providers not covered here. For more detailed information and access to a broad catalog of data products, the report encourages contacting Eagle Alpha directly.